The 3rd World Congress on
CONTROVERSIES IN OPHTHALMOLOGY
Anterior Segment, Retina, Glaucoma

ISTANBUL, TURKEY • MARCH 22-25, 2012

SPONSORSHIP AND EXHIBITION
prospectus

www.cometecmed.com/cophy • cophy@comtecmed.com
We are pleased to announce the 3rd World Congress on Controversies in Ophthalmology (COPHy), which will take place in Istanbul, Turkey, March 22-25, 2012. The highly successful 1st and 2nd COPHy Congresses, which took place in Prague and Barcelona respectively, attracted over 1,300 participants from 58 countries. Based on the success of the previous congresses, and on the feedback from COPHy participants, COPHy Istanbul will be devoted to evidence-based debates and discussions amongst chairpersons, speakers and the audience, all of whom will examine and analyze the most relevant issues raised during the course of 2011 within the field of Ophthalmology.

This time our emphasis will be directed on Retina, Anterior Segment and Glaucoma. We invite you to participate in the 3rd World Congress of Controversies in Ophthalmology (COPHy), the next edition of many future congresses to come.

As always, there are several opportunities and industry sponsored activities available and would be happy to tailor to your needs.

We cordially invite you to join us as sponsors and partners of COPHy 2012 in the beautiful city of Istanbul, where Europe and Asia come together.

Sincerely,

Prof. Neil Bressler, USA
Prof. Anat Loewenstein, Israel
Co-Chairpersons
CONGRESS PROFILE

Since its launch in 2010, COPHy is establishing itself as a unique educational meeting where physicians can meet with outstanding experts in major Ophthalmology fields, and be updated on the most pressing clinical questions of the day. COPHy is the only congress of its kind that focuses mainly on controversial issues.

AIMS OF THE CONGRESS

• To provide the participants insight into major changes in the rapidly evolving field of Ophthalmology
• To provide an effective forum for discussing and debating unsolved issues by allowing ample time for speakers/audience discussion
• To promulgate ethics and standards of practice and treatment
• To bridge gaps between expansion of basic science and information, and their consolidation into clinical practice
• To make it possible for the industry to meet the outstanding experts in the field, and to update international participants on pressing clinical and technological questions of the day

PAST CONGRESS STATISTICS

<table>
<thead>
<tr>
<th>COPHy</th>
<th>Prague 2010</th>
<th>Barcelona 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sessions</td>
<td>26 (including 3 symposia)</td>
<td>26 (including 2 symposia)</td>
</tr>
<tr>
<td>Debates</td>
<td>49</td>
<td>41</td>
</tr>
<tr>
<td>Faculty</td>
<td>75</td>
<td>90</td>
</tr>
<tr>
<td>Posters Presentations</td>
<td>97</td>
<td>82</td>
</tr>
<tr>
<td>Countries</td>
<td>50</td>
<td>47</td>
</tr>
</tbody>
</table>

DEMOGRAPHICS

The 1st World Congress on Controversies in Ophthalmology (COPHy)
Prague, Czech Republic • March 4-7, 2010

The 2nd World Congress on Controversies in Ophthalmology (COPHy)
Barcelona, Spain • March 3-6, 2011

Western Europe 41.5%
Eastern Europe 19%
Middle East 28.5%
North America 7.5%
Latin America 0.5%
Africa 0.5%
Asia Pacific 2.5%

Western Europe 59%
Eastern Europe 12%
Middle East 17.5%
North America 8%
Latin America 1.5%
Africa 0.5%
Asia Pacific 1.5%
# TIMETABLE

## Thursday, March 22, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>

## Friday, March 23, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15-08:15</td>
<td>Breakfast session</td>
</tr>
</tbody>
</table>
| 08:30-10:00| Hall A: Controversies Regarding Treatment of Neovascular AMD  
Hall B: Controversies in Medical Treatment of Glaucoma  
Hall C: Cataract: Intraocular Lenses |
| 10:00-10:30| Coffee Break and Visit Exhibits               |
| 10:30-12:00| Hall A: Controversies Regarding Management of Macular Edema from Retinal Vein Occlusions  
Hall B: Controversies in Glaucoma Diagnosis & Progression  
Hall C: Cataract: Complicated Situations |
| 12:00-12:30| Break – Visit Exhibits                       |
| 12:30-13:45| Lunch and Plenary Session                    |
| 13:45-15:00| OCT Marathon Symposium                       |
| 15:00-15:30| Coffee Break and Visit Exhibits               |
| 15:30-17:00| Hall A: Controversies on Imaging: Autofluorescence, OCT  
Hall B: Controversies in Laser Treatment in Glaucoma  
Hall C: Uveitis: Bechet’s Disease & more |
| 17:00-18:30| Hall A: Tumor/ROP: Melanoma, Retinoblastoma, Lymphoma  
Hall B: Idiopathic Intracranial Hypertension & more  
Hall C: PEDIATRIC OPHTHALMOLOGY |

## Saturday, March 24, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15-08:15</td>
<td>Breakfast session</td>
</tr>
</tbody>
</table>
| 08:30-10:00| Hall A: Controversies in Treatment of Diabetic Macular Edema  
Hall B: Controversies in Surgical Management of Glaucoma  
Hall C: Cornea: Controversies in Modern Graft Technologies |
| 10:00-10:30| Coffee Break and Visit Exhibits               |
| 10:30-12:00| Symposium                                    |
| 12:00-12:30| Break – Visit Exhibits                       |
| 12:30-13:45| Lunch and Plenary Session                    |
| 13:45-15:00| Surgical Marathon Symposium                  |
| 15:00-15:30| Coffee Break and Visit Exhibits               |
| 15:30-17:00| Hall A: Surgery: Innovations                
Hall B: NEURO-OPHTHALMOLOGY II: Temporal Arteritis  
Hall C: ANTERIOR SEGMENT V: Refractive Surgery: Presbyopia & High Refractive Errors |
| 17:00-18:30| Hall A: Trauma: Orbital, Outer & Posterior Segment  
Hall B:  
Hall C: |

## Sunday, March 25, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Travel Day</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAM

FRIDAY, MARCH 23, 2012

Hall A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08:30-10:00 | RETINA I  
CONTROVERSIES REGARDING TREATMENT OF NEOVASCULAR AMD  
Capsule: Controversies in neovascular AMD treatment: CATT and beyond  
Chairpersons: S. Bressler, USA; G. Soubrane, France |
| 08:30-08:40 | Ranibizumab monthly or PRN  
S. Bressler, USA |
| 08:40-08:45 | Q&A from the audience, panel, chairpersons |
| 08:45-08:55 | Bevacizumab monthly or PRN  
TBA |
| 08:55-09:00 | Q&A from the audience, panel, chairpersons |
| 09:00-09:10 | VEGF-Trap eye at fixed dosing or PRN  
U. Schmidt-Erfurth, Austria |
| 09:10-09:15 | Q&A from the audience, panel, chairpersons |
| 09:15-10:00 | Roundtable discussion  
First-line therapy when finance is not the issue (a. Ranibizumab monthly, b. Ranibizumab PRN, c. Bevacizumab monthly, d. Bevacizumab PRN, e. VEGF-trap loading and every 2 months, f. Combination Ranibizumab and irradiation)  
Approach to non-responders (a. Definition, b. Continue same anti-VEGF, c. Switch to another anti-VEGF, d. Add radiation, e. Observe)  
Polypoidal or RAP lesion need specific approach  
Moderator: N. Bressler, USA  
Panel: S. Bressler, USA  
B. Eldem, Turkey  
O. Gelisken, Turkey  
U. Schmidt-Erfurth, Austria |

10:00-10:30 | Coffee Break and Visit Exhibits |

10:30-12:00 | RETINA II  
CONTROVERSIES REGARDING MANAGEMENT OF MACULAR EDEMA FROM RETINAL VEIN OCCLUSIONS  
Capsule: Branch vein occlusion and macular edema – multiple optional treatments  
Chairpersons: F. Bandello, Italy; G. Coscas, France |
| 10:30-10:40 | Ranibizumab or Bevacizumab monthly for 6 months  
F. Bandello, Italy |
| 10:40-10:45 | Q&A from the audience, panel, chairpersons |
| 10:45-10:55 | Ranibizumab or Bevacizumab PRN  
A. Augustin, Germany |
| 10:55-11:00 | Q&A from the audience, panel, chairpersons |
| 11:00-11:10 | Iluvien or Ozurdex  
A. Loewenstein, Israel |
| 11:00-11:15 | Q&A from the audience, panel, chairpersons |
FRIDAY, MARCH 23, 2012

Hall A

10:30-12:00 RETINA II [continued]

11:15-12:00 Roundtable discussion
First-line therapy when finance is not an issue (a. Ranibizumab, b. Bevacizumab, c. VEGF-trap, fixed regimen or PRN for first 6 months, d. Ozurdex)

After 6 months (a. Ranibizumab PRN, Bevacizumab PRN, VEGF-trap PRN, b. Add grid laser, c. Add grid laser only if anti-VEGF does not work, d. Ozurdex)

Moderator: F. Bandello, Italy
Panel:
S. Arf, Turkey
A. Augustin, Germany
F. Batioglu, Turkey
G. Coscas, France
A. Loewenstein, Israel

12:00-12:30 Break – Visit Exhibits

15:15-16:45 RETINA III

CONTROVERSIES ON IMAGING: AUTOFLUORESCENCE, OCT

Capsule: Imaging in the present and future
Chairpersons: J. Cunha-Vaz, Portugal; U. Schmidt-Erfurth, Austria

15:15-15:25 Autofluorescence: Part of standard care
TBA

15:25-15:30 Q&A from the audience, panel, chairpersons

15:30-15:40 Autofluorescence: Not part of standard care
H. Scholl, USA

15:40-15:45 Q&A from the audience, panel, chairpersons

15:45-15:55 SD OCT leads to different outcomes than TD OCT
U. Schmidt-Erfurth, Austria

15:55-16:00 Q&A from the audience, panel, chairpersons

16:00-16:10 SD OCT does not lead to different outcomes than TD OCT
S. Bressler, USA

16:10-16:15 Q&A from the audience, panel, chairpersons

16:15-16:45 Discussion

Moderator: H. Scholl, USA
Panel:
S. Bressler, USA
J. Cunha-Vaz, Portugal
U. Schmidt-Erfurth, Austria
### SCIENTIFIC PROGRAM

#### FRIDAY, MARCH 23, 2012

**Hall A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45-18:15</td>
<td>RETINA IV TUMOR/ROP: MELANOMA, RETINOBLASTOMA, LYMPHOMA</td>
<td><strong>Chairperson:</strong> J. Pe’er, Israel</td>
</tr>
<tr>
<td>16:45-17:15</td>
<td>DEBATE I: SUPRA INTRA-ARTERIAL CHEMOTHERAPY</td>
<td></td>
</tr>
<tr>
<td>16:45-16:55</td>
<td>Pro: H. Kiratli, Turkey</td>
<td></td>
</tr>
<tr>
<td>16:55-17:05</td>
<td>Con: K. Gunduz, Turkey</td>
<td></td>
</tr>
<tr>
<td>17:05-17:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>17:15-17:45</td>
<td>DEBATE II: FNAB IN UVEAL MELANOMA</td>
<td></td>
</tr>
<tr>
<td>17:15-17:25</td>
<td>Pro: TBA</td>
<td></td>
</tr>
<tr>
<td>17:25-17:35</td>
<td>Con: H. Kiratli, Turkey</td>
<td></td>
</tr>
<tr>
<td>17:35-17:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>17:45-18:15</td>
<td>DEBATE III: TREATMENT OF VITREO-RETINAL LYMPHOMA</td>
<td>In favor of intravitreal injections of methotrexate: J. Pe’er, Israel</td>
</tr>
<tr>
<td>17:45-17:55</td>
<td>In favor of other modalities (systemic chemotherapy and irradiation): K. Gunduz, Turkey</td>
<td></td>
</tr>
<tr>
<td>17:55-18:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:05-18:15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### SATURDAY, MARCH 24, 2012

**Hall A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>RETINA V CONTROVERSIES IN TREATMENT OF DIABETIC MACULAR EDEMA</td>
<td><strong>Capsule:</strong> Management of diabetic retinopathy in 2012  <strong>Chairpersons:</strong> A. Augustin, Germany; B. Eldem, Turkey</td>
</tr>
<tr>
<td>08:30-08:40</td>
<td>Focal Grid laser</td>
<td>G. Soubrane, France</td>
</tr>
<tr>
<td>08:40-08:45</td>
<td>Q&amp;A from the audience, panel, chairpersons</td>
<td></td>
</tr>
<tr>
<td>08:45-08:55</td>
<td>Anti-VEGF therapy (e.g. DRCR Network Algorithm)</td>
<td>S. Bressler, USA</td>
</tr>
<tr>
<td>08:55-09:00</td>
<td>Q&amp;A from the audience, panel, chairpersons</td>
<td></td>
</tr>
<tr>
<td>09:00-09:10</td>
<td>Other treatments (e.g. combination therapy)</td>
<td>B. Eldem, Turkey</td>
</tr>
<tr>
<td>09:10-09:15</td>
<td>Q&amp;A from the audience, panel, chairpersons</td>
<td></td>
</tr>
<tr>
<td>09:15-10:00</td>
<td>Roundtable discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is it time to give up? (a. Fluorescein angiography in the treatment of diabetic macular edema, b. Diffuse vs. Focal macular edema, c. Clinically significant macular edema, c. Fundus photography, d. Contact lens biomicroscopy)</td>
<td>Moderator: F. Bandello, Italy</td>
</tr>
<tr>
<td></td>
<td>Panel:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Arf, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Augustin, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>F. Batioglu, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Bressler, USA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Cunha-Vaz, Portugal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Eldem, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td>G. Soubrane, France</td>
<td></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break and Visit Exhibits</td>
<td></td>
</tr>
</tbody>
</table>
## SCIENTIFIC PROGRAM

### SATURDAY, MARCH 24, 2012

**Hall A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15-16:45</td>
<td>RETINA VI&lt;br&gt;SURGERY: INNOVATIONS&lt;br&gt;&lt;br&gt;Capsule: New technologies and old problems&lt;br&gt;&lt;br&gt;Chairpersons: A. Augustin, Germany; W. Mieler, USA; J. Moisseiev, Israel</td>
</tr>
<tr>
<td>15:15-15:45</td>
<td>DEBATE I: THE BEST TREATMENT FOR VITREORETINAL INTERFACE DISORDERS (MACULAR HOLE, VITREOMACULAR TRACTION, LAMELLER HOLES)&lt;br&gt;&lt;br&gt;15:15-15:25 The natural history warrants observation: F. Boscia, Italy&lt;br&gt;&lt;br&gt;15:25-15:35 Vitrectomy should be performed: S. Rizzo, Italy&lt;br&gt;&lt;br&gt;15:35-15:45 Microplasmin: W. Mieler, USA</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>Case presentations and Panel discussion (2-3 cases)&lt;br&gt;&lt;br&gt;Presenter: J. Moisseiev, Israel&lt;br&gt;&lt;br&gt;Panel: F. Boscia, Italy&lt;br&gt; M. Karacorlu, Turkey&lt;br&gt; J. Nawrocki, Poland&lt;br&gt; S. Rizzo, Italy</td>
</tr>
<tr>
<td>16:45-18:15</td>
<td>RETINA VII&lt;br&gt;TRAUMA: ORBITAL, OUTER &amp; POSTERIOR SEGMENT&lt;br&gt;&lt;br&gt;Capsule: Ocular trauma treatment&lt;br&gt;&lt;br&gt;Chairpersons: J. Moisseiev, Israel; W. Schrader, Germany</td>
</tr>
<tr>
<td>16:45-17:15</td>
<td>Update Lectures&lt;br&gt;&lt;br&gt;16:45-16:55 Orbital and periorbital trauma&lt;br&gt;&lt;br&gt;N. Rosen, Israel&lt;br&gt;&lt;br&gt;16:55-17:05 Surgery for traumatic subluxation of the crystalline lens&lt;br&gt;&lt;br&gt;D. Sachs, Israel&lt;br&gt;&lt;br&gt;17:05-17:15 Discussion</td>
</tr>
<tr>
<td>17:15-17:45</td>
<td>DEBATE: REMOVAL OF IOFB – TIMING AND SURGICAL APPROACH&lt;br&gt;&lt;br&gt;17:15-17:25 Pro: Immediate removal of the IOFB is critical: TBA&lt;br&gt;&lt;br&gt;17:25-17:35 Con: Delayed removal is safe: W. Mieler, USA&lt;br&gt;&lt;br&gt;17:35-17:45 Discussion</td>
</tr>
<tr>
<td>17:45-18:15</td>
<td>Case presentation and Panel discussion: Posterior segment trauma&lt;br&gt;&lt;br&gt;Moderators: J. Moisseiev, Israel; W. Schrader, Germany&lt;br&gt;&lt;br&gt;Panel: B. Eldem, Turkey&lt;br&gt; M. Karacorlu, Turkey&lt;br&gt; W. Mieler, USA</td>
</tr>
</tbody>
</table>
## SCIENTIFIC PROGRAM

### FRIDAY, MARCH 23, 2012

#### Hall C

### 08:30-10:00  ANTERIOR SEGMENT I

**CAPTARACT: INTRAOCULAR LENSES**

**Capsule:**
What is the best IOL?

Chairpersons: [J. Alio](#), Spain; [E. Assia](#), Israel; [W.J. Stark](#), USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td><strong>DEBATE I: IOL POWER CALCULATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>08:30-08:40</td>
<td>Essentials for accuracy (IOL Master/ Ultrason / Lenstar / Pentacam / Atlas ...): TBA</td>
<td></td>
</tr>
<tr>
<td>08:40-08:50</td>
<td>How to calculate in high myopia / hypermetropia: <a href="#">B.S. Aslan</a>, Turkey</td>
<td></td>
</tr>
<tr>
<td>08:50-09:00</td>
<td>Wrong power implantation: Exchange or piggyback? TBA</td>
<td></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td><strong>DEBATE II: SURGICAL CORRECTION OF MALPOSITIONED LENSES (CRYSTALLINE &amp; IOL)</strong></td>
<td></td>
</tr>
<tr>
<td>09:00-09:20</td>
<td>Iris vs. Scleral fixation: <a href="#">W.J. Stark</a>, USA</td>
<td></td>
</tr>
<tr>
<td>09:20-09:30</td>
<td>Capsule supporting devices: <a href="#">E. Assia</a>, Israel</td>
<td></td>
</tr>
<tr>
<td>09:30-09:40</td>
<td>Reposition vs. Exchange: TBA</td>
<td></td>
</tr>
<tr>
<td>09:40-10:00</td>
<td>Roundtable discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Controversies in pediatric cataract surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overview: IOL implantation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>What age?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>When?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Power calculation?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Design and material, PCCC capture?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: <a href="#">E. Assia</a>, Israel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel: <a href="#">J. Alio</a>, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="#">B.S. Aslan</a>, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="#">S. Kaynak</a>, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="#">W.J. Stark</a>, USA</td>
<td></td>
</tr>
</tbody>
</table>

### Coffee Break and Visit Exhibits

### 10:00-10:30

### 10:30-12:00  ANTERIOR SEGMENT II

**CAPTARACT: COMPLICATED SITUATIONS**

**Capsule:**
Laser, toric IOL's role in present and future

Chairpersons: [J. Alio](#), Spain; [E. Assia](#), Israel; [W.J. Stark](#), USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-11:00</td>
<td><strong>DEBATE I: TORIC IOL</strong></td>
<td></td>
</tr>
<tr>
<td>10:30-10:40</td>
<td>An option or a must? <a href="#">W.J. Stark</a>, USA</td>
<td></td>
</tr>
<tr>
<td>10:40-10:50</td>
<td>Accuracy, stability, surprises? TBA</td>
<td></td>
</tr>
<tr>
<td>10:50-11:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td><strong>DEBATE II: LASER CATARACT SURGERY</strong></td>
<td></td>
</tr>
<tr>
<td>11:00-11:10</td>
<td>A real advantage over current technology: <a href="#">J. Alio</a>, Spain</td>
<td></td>
</tr>
<tr>
<td>11:10-11:20</td>
<td>Expensive gimmick: <a href="#">S. Kaynak</a>, Turkey</td>
<td></td>
</tr>
<tr>
<td>11:20-11:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Roundtable discussion: Controversial surgical approach</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Special cases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: <a href="#">E. Assia</a>, Israel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel: <a href="#">J. Alio</a>, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="#">B.S. Aslan</a>, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="#">S. Kaynak</a>, Turkey</td>
<td></td>
</tr>
<tr>
<td></td>
<td><a href="#">W.J. Stark</a>, USA</td>
<td></td>
</tr>
</tbody>
</table>

### Break – Visit Exhibits

### 12:00-12:30
## Scientific Program

### Friday, March 23, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15-16:45</td>
<td><strong>Anterior Segment III</strong>&lt;br&gt;Uveitis: Bechet’s Disease and More&lt;br&gt;Capsule: Unsolved issues in uveitis&lt;br&gt;Chairperson: S. Lightman, UK</td>
</tr>
<tr>
<td>15:15-15:45</td>
<td><strong>Debate I:</strong> Bechet’s Disease Treatment: Which Immunosuppressive Agents Should We Use?&lt;br&gt;Conventional including cyclosporine? TBA&lt;br&gt;Biological agents: TBA&lt;br&gt;Commentator: S. Lightman, UK</td>
</tr>
<tr>
<td>15:45-16:15</td>
<td><strong>Debate II:</strong> Birdshot Chorioretinopathy: Is Long-Term Immunosuppression Indicated?&lt;br&gt;Yes: S. Lightman, UK&lt;br&gt;No: TBA&lt;br&gt;Commentator: S. Taylor, UK</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td><strong>Debate III:</strong> Treatment of Uveitis-Related Cystoid Macular Edema&lt;br&gt;Intravitreal or subtenon corticosteroids: S. Lightman, UK&lt;br&gt;Other intravitreal drugs: S. Taylor, UK&lt;br&gt;Commentator: M. DeSmet, The Netherlands</td>
</tr>
</tbody>
</table>

### Saturday, March 24, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td><strong>Anterior Segment IV</strong>&lt;br&gt;Cornea: Controversies in Modern Graft Technologies&lt;br&gt;Chairpersons: J. Alio, Spain; E. Assia, Israel; W.J. Stark, USA</td>
</tr>
<tr>
<td>08:30-09:00</td>
<td><strong>Debate I:</strong> Modern Corneal Grafting Surgery: Femtosecond vs. Conventional – Cost Effectiveness, Advantages, Disadvantages, Outcomes&lt;br&gt;Femtosecond laser is better than conventional surgical techniques: J. Alio, Spain&lt;br&gt;Femtosecond laser is not better than conventional surgical techniques: TBA&lt;br&gt;Discussion</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td><strong>Debate II:</strong> Modern Corneal Grafting Surgery: Collagen Cross-Linking (With the Different Methods Used Today, Avedro Microwave Technology, CCL + OK, Intracorneal Rings, Intracorneal Segments)&lt;br&gt;The Athens protocol and other combined protocols: TBA&lt;br&gt;Collagen cross-linking should be done separately: TBA&lt;br&gt;Discussion</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Roundtable discussion&lt;br&gt;Molding the cornea without grafting: The corneoplastic surgery concept&lt;br&gt;Moderator: E. Akpek, USA (10 minute presentation)&lt;br&gt;Panel: W.J. Stark, USA</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break and Visit Exhibits</td>
</tr>
</tbody>
</table>
### SATURDAY, MARCH 24, 2012

#### Hall C

**15:15-16:45 ANTERIOR SEGMENT V**  
**REFRACTIVE SURGERY: PRESBYOPIA & HIGH REFRACTIVE ERRORS**  
*Capsule:* Treatment for presbyopia and high refractive errors  
Chairpersons: J. Alio, Spain; E. Assia, Israel; W.J. Stark, USA  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15-15:45</td>
<td>DEBATE I: PRESBYOPIA SURGERY</td>
</tr>
<tr>
<td>15:15-15:25</td>
<td>Multifocal LASIK: J. Alio, Spain</td>
</tr>
<tr>
<td>15:25-15:35</td>
<td>Femtosecond intrastromal presbyopic treatment: TBA</td>
</tr>
<tr>
<td>15:35-15:45</td>
<td>Presbyopia IOL: TBA</td>
</tr>
<tr>
<td>15:45-16:15</td>
<td>DEBATE II: CORNEAL REFRACTIVE SURGERY IN THE CORRECTION OF HIGH REFRACTIVE ERRORS</td>
</tr>
<tr>
<td>15:45-15:55</td>
<td>Clear lens extraction? E. Assia, Israel</td>
</tr>
<tr>
<td>15:55-16:05</td>
<td>Phakic IOLs? TBA</td>
</tr>
<tr>
<td>16:05-16:15</td>
<td>LASIK surgery? J. Alio, Spain</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>DEBATE III: PHAKIC IOLS</td>
</tr>
<tr>
<td>16:15-16:25</td>
<td>Angle supported: TBA</td>
</tr>
<tr>
<td>16:25-16:35</td>
<td>Iris fixated: TBA</td>
</tr>
<tr>
<td>16:35-16:45</td>
<td>Posterior chamber: TBA</td>
</tr>
</tbody>
</table>

### FRIDAY, MARCH 23, 2012

#### Hall B

**08:30-10:00 GLAUCOMA I**  
CONTROVERSIES IN MEDICAL TREATMENT OF GLAUCOMA  
Chairpersons: A. Heijl, Sweden; K. Martin, UK  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>DEBATE I: INITIAL MONOTHERAPY IS AN OBSOLETE DOGMA</td>
</tr>
<tr>
<td>08:30-08:40</td>
<td>Yes: A. Heijl, Sweden</td>
</tr>
<tr>
<td>08:40-08:50</td>
<td>No: TBA</td>
</tr>
<tr>
<td>08:50-09:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>DEBATE II: ARE ANY CURRENTLY AVAILABLE DRUGS NEUROPROTECTIVE?</td>
</tr>
<tr>
<td>09:00-09:10</td>
<td>Yes: S. Gandolfi, Italy</td>
</tr>
<tr>
<td>09:10-09:20</td>
<td>No: K. Martin, UK</td>
</tr>
<tr>
<td>09:20-09:30</td>
<td>Discussion</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>DEBATE III: EXFOLIATION AND OCULAR HYPERTENSION IS SUCH A DANGEROUS COMBINATION THAT ALL PATIENTS SHOULD BE TREATED</td>
</tr>
<tr>
<td>09:30-09:40</td>
<td>Yes: A. Heijl, Sweden</td>
</tr>
<tr>
<td>09:40-09:50</td>
<td>No: TBA</td>
</tr>
<tr>
<td>09:50-10:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break and Visit Exhibits</td>
</tr>
</tbody>
</table>
## SCIENTIFIC PROGRAM

### FRIDAY, MARCH 23, 2012

**Hall B**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairperson</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-12:00</td>
<td><strong>GLAUCOMA II</strong> CONTROVERSIES IN GLAUCOMA DIAGNOSIS AND PROGRESSION</td>
<td>A. Heijl, Sweden; K. Martin, UK</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td><strong>DEBATE I: MOLECULAR BIOMARKERS WILL BE USEFUL</strong></td>
<td></td>
</tr>
<tr>
<td>10:30-10:40</td>
<td>Yes: TBA</td>
<td></td>
</tr>
<tr>
<td>10:40-10:50</td>
<td>No: TBA</td>
<td></td>
</tr>
<tr>
<td>10:50-11:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td><strong>DEBATE II: IT IS TIME TO STOP CONFUSING OPHTHALMOLOGISTS WITH TALK OF SO-CALLED “SELECTIVE PERIMETRY”</strong></td>
<td></td>
</tr>
<tr>
<td>11:00-11:10</td>
<td>Yes: TBA</td>
<td></td>
</tr>
<tr>
<td>11:10-11:20</td>
<td>No: TBA</td>
<td></td>
</tr>
<tr>
<td>11:20-11:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td><strong>DEBATE III: HOW BEST TO ASSESS PROGRESSION IN THE FUTURE?</strong></td>
<td></td>
</tr>
<tr>
<td>11:30-11:40</td>
<td>Smarter use of existing methodologies: TBA</td>
<td></td>
</tr>
<tr>
<td>11:40-11:50</td>
<td>Image sick and dying cells: K. Martin, UK</td>
<td></td>
</tr>
<tr>
<td>11:50-12:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Break – Visit Exhibits</td>
<td></td>
</tr>
<tr>
<td>15:15-16:45</td>
<td><strong>GLAUCOMA III</strong> CONTROVERSIES IN LASER TREATMENT IN GLAUCOMA</td>
<td>A. Heijl, Sweden</td>
</tr>
<tr>
<td>15:15-15:45</td>
<td><strong>DEBATE I: SLT SHOULD BE FIRST-LINE?</strong></td>
<td></td>
</tr>
<tr>
<td>15:15-15:25</td>
<td>Yes: S. Gandolfi, Italy</td>
<td></td>
</tr>
<tr>
<td>15:25-15:35</td>
<td>No: TBA</td>
<td></td>
</tr>
<tr>
<td>15:35-15:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:45-16:15</td>
<td><strong>DEBATE II: SHOULD ENDODIODE BE USED MORE?</strong></td>
<td></td>
</tr>
<tr>
<td>15:45-15:55</td>
<td>Yes: P. Bloom, UK</td>
<td></td>
</tr>
<tr>
<td>15:55-16:05</td>
<td>No: S. Vernon, UK</td>
<td></td>
</tr>
<tr>
<td>16:05-16:15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:15-16:45</td>
<td><strong>DEBATE III: SHOULD IRIDOPLASTY BE USED MORE?</strong></td>
<td></td>
</tr>
<tr>
<td>16:15-16:25</td>
<td>Yes: TBA</td>
<td></td>
</tr>
<tr>
<td>16:25-16:35</td>
<td>No: TBA</td>
<td></td>
</tr>
<tr>
<td>16:35-16:45</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
## SATURDAY, MARCH 24, 2012

### Hall B

#### 08:30-10:00  GLAUCOMA IV

**CONTROVERSIES IN SURGICAL MANAGEMENT OF GLAUCOMA**

Chairperson: A. Heijl, Sweden

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:30</td>
<td><strong>DEBATE I: WHAT IS THE MOST PROMISING NEW SURGICAL TECHNIQUE?</strong></td>
<td></td>
</tr>
<tr>
<td>08:30-08:40</td>
<td>iStent: P. Bloom, UK</td>
<td></td>
</tr>
<tr>
<td>08:40-08:50</td>
<td>Trabectome: TBA</td>
<td></td>
</tr>
<tr>
<td>08:50-09:00</td>
<td>Canaloplasty: TBA</td>
<td></td>
</tr>
<tr>
<td>09:00-09:10</td>
<td>Better use of conventional tubes: TBA</td>
<td></td>
</tr>
<tr>
<td>09:10-09:30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td><strong>DEBATE II: WHAT IS BEST THE TREATMENT FOR NEOVASCULAR GLAUCOMA?</strong></td>
<td></td>
</tr>
<tr>
<td>09:30-09:40</td>
<td>Tubes: TBA</td>
<td></td>
</tr>
<tr>
<td>09:40-09:50</td>
<td>Anti-VEGF + trabeculectomy: H. Levkovitch-Verbin, Israel</td>
<td></td>
</tr>
<tr>
<td>09:50-10:00</td>
<td>Cycloablation: S. Vernon, UK</td>
<td></td>
</tr>
</tbody>
</table>

10:00-10:30  Coffee Break and Visit Exhibits

#### 16:45-18:15  NEURO-OPHTHALMOLOGY I

**IDIOPATHIC INTRACRANIAL HYPERTENSION & MORE**

Chairperson: N. Miller, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Symposium on &quot;idiopathic&quot; intracranial hypertension</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45-17:15</td>
<td>1) What is your evaluation for the typical patient?</td>
<td>A. Lee, USA</td>
</tr>
<tr>
<td></td>
<td>2) What is your evaluation for the atypical patient?</td>
<td>A. Kesler, Israel</td>
</tr>
<tr>
<td></td>
<td>3) A patient with presumed IIH has no evidence of optic neuropathy. What is your treatment and what do you do if the patient worsens?</td>
<td>A. Arnold, USA</td>
</tr>
<tr>
<td></td>
<td>4) A patient with presumed IIH has evidence of an optic neuropathy at presentation. What is your treatment?</td>
<td>N. Miller, USA</td>
</tr>
<tr>
<td></td>
<td>5) A patient with presumed IIH has no evidence of optic neuropathy and there is evidence of venous sinus stenosis?</td>
<td>TBA</td>
</tr>
<tr>
<td></td>
<td>6) A patient with presumed IIH has evidence of an optic neuropathy at presentation and has an area of venous sinus stenosis. Would you stent immediately?</td>
<td>TBA</td>
</tr>
</tbody>
</table>
**FRIDAY, MARCH 23, 2012**

**Hall B**

**16:45-18:15 NEURO-OPHTHALMOLOGY I** [continued]

**17:15-18:15 Case presentations**

Moderator: N. Miller, USA

1) A patient with routine optic neuritis  
A. Kesler, Israel; A. Lee, USA

2) A patient with bilateral acute optic neuritis  
TBA

3) A patient with Leber Hereditary Optic Neuropathy  
A. Arnold, USA; P. Aydin, Turkey; A. Kesler, Israel

4) A patient with non-arthritic anterior ischemic optic neuropathy who is considering cataract surgery in the other eye  
A. Lee, USA

5) A patient with traumatic optic neuropathy  
A. Arnold, USA; A. Kesler, Israel

6) A patient with a central retinal artery occlusion: Europe vs. USA  
A. Lee, USA

7) A patient with congenital “motor” type nystagmus  
All Speakers on the panel

**15:15-16:45 NEURO-OPHTHALMOLOGY II**

**TEMPORAL ARTERITIS**

Chairpersons: P. Aydin, Turkey; N. Miller, USA

**15:15-15:45 Symposium on Giant Cell (Temporal Arteritis)**

Moderator: P. Aydin, Turkey

1) Diagnosis of GCA in a patient with unilateral AION  
TBA

2) Treatment of GCA in a patient with AION  
A. Arnold, USA

3) Treatment of GCA in a patient with diplopia  
A. Lee, USA

4) Treatment of a patient who progresses despite steroids  
N. Miller, USA

**15:45-16:45 Case presentations**

Moderator: N. Miller, USA

1) A patient with radiation optic neuropathy: Do you treat? If so, with what?  
A. Arnold, USA

2) Child with optic glioma that progresses: What is your treatment?  
P. Aydin, Turkey

3) Adult-onset MG: What is your initial treatment?  
A. Kesler, Israel

4) Young patient with NAION: What is your work-up?  
A. Lee, USA

5) A patient with elevated discs and a headache  
A. Arnold, USA

6) A young woman with transient monocular visual loss  
A. Kesler, Israel

7) Should one recommend selenium for mild TED?  
All speakers on the panel

**SATURDAY, MARCH 24, 2012**

**Hall B**

**15:15-16:45 NEURO-OPHTHALMOLOGY II**

**TEMPORAL ARTERITIS**

Chairpersons: P. Aydin, Turkey; N. Miller, USA

**15:15-15:45 Symposium on Giant Cell (Temporal Arteritis)**

Moderator: P. Aydin, Turkey

1) Diagnosis of GCA in a patient with unilateral AION  
TBA

2) Treatment of GCA in a patient with AION  
A. Arnold, USA

3) Treatment of GCA in a patient with diplopia  
A. Lee, USA

4) Treatment of a patient who progresses despite steroids  
N. Miller, USA

**15:45-16:45 Case presentations**

Moderator: N. Miller, USA

1) A patient with radiation optic neuropathy: Do you treat? If so, with what?  
A. Arnold, USA

2) Child with optic glioma that progresses: What is your treatment?  
P. Aydin, Turkey

3) Adult-onset MG: What is your initial treatment?  
A. Kesler, Israel

4) Young patient with NAION: What is your work-up?  
A. Lee, USA

5) A patient with elevated discs and a headache  
A. Arnold, USA

6) A young woman with transient monocular visual loss  
A. Kesler, Israel

7) Should one recommend selenium for mild TED?  
All speakers on the panel
### SCIENTIFIC PROGRAM

#### FRIDAY, MARCH 23, 2012

**Hall C**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45-18:15</td>
<td><strong>PEDIATRIC OPHTHALMOLOGY</strong>&lt;br&gt;ROP, CATARACT, GLAUCOMA&lt;br&gt;&lt;br&gt;<em>Capsule:</em> Pediatric ophthalmology – more than meets the eye&lt;br&gt;<em>Chairperson:</em> K.K. Nischal, UK</td>
</tr>
</tbody>
</table>
| 16:45-17:15| **DEBATE I: RETINOPATHY OF PREMATURITY**
  - 16:45-16:55 Diode laser is still the treatment of choice: TBA
  - 16:55-17:05 Treatment with Avastin is the practice of choice: P. Nucci, Italy
  - 17:05-17:15 Discussion |
| 17:15-17:45| **DEBATE II: CATARACT SURGERY IN CHILDREN**
  - 17:15-17:25 Posterior capsulotomy should always be performed: TBA
  - 17:25-17:35 The need for capsulotomy is determined by the individual case: K.K. Nischal, UK
  - 17:35-17:45 Discussion |
| 17:45-18:15| **DEBATE III: GLAUCOMA SURGERY IN CHILDREN**
  - 17:45-17:55 Goniotomy or trabeculectomy depending on the age and mechanism: D. Bremond Gignac, France
  - 17:55-18:05 Specific techniques: Enophotocoagulation to ciliary body, or other: TBA
  - 18:05-18:15 Discussion |
# CATEGORIES OF SPONSORSHIP

## PRESIDENTIAL CIRCLE
(limited to one company)

€90,000 and up

Presidential Circle category will have priority in choosing up to two additional sponsorship items with a total value of €15,000

## PLATINUM

€75,000 and up

Platinum category will have priority in choosing up to two additional sponsorship items with a total value of €10,000

## GOLD

€50,000 - €75,000

Gold category will have priority in choosing one additional sponsorship item with a total value of €5,000

## SILVER

€30,000 - €50,000

## BRONZE

€10,000 - €30,000

## SPONSOR

€3,000 - €10,000
A company may provide an unrestricted grant to support an existing session of particular interest to the company (see attached Programs in Retina, Anterior Segment, and Glaucoma).

Dates: Friday or Saturday or Sunday.

PROVIDED BY THE CONGRESS

Educational Session
- Grant includes costs of session hall and basic audiovisual equipment
- Grant includes costs of 5 Moderators, Chairs, Speakers during that session

Advertisement Package
- Company profile in the Congress Program Book
- One full page color advertisement in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage
- Brochure in the participants’ bags

Promotion
- Company logo on regular announcements to Congress Database

PROVIDED BY THE COMPANY

Exhibition
- Exhibition space will be charged at a sponsor rate of Euro 450 per each sq.m

OPTIONAL ADDITIONAL COST

Video or and Audio Web Cast
- Recording of presentation to allow podcast of session, available on the COPHy Website for up to a year.
SCIENTIFIC SPONSORSHIP OPPORTUNITIES

NEW

BREAKFAST INDUSTRIAL SYMPOSIUM (NON-CME APPROVED)

€40,000

The expenses (travel, accommodation, honorarium, and registration) of the Speakers of a sponsored Industrial Symposium are additional and the responsibility of the Sponsor.

A company may organize a Breakfast Industrial (non-CME approved) symposium (60 minutes; from 7:15 AM to 8:15 AM). The topic will be subject to approval by the Chairpersons of the Conference (Drs. Bressler and Loewenstein) and is expected to follow the controversies theme of the meeting. The Speakers or Moderators will be subject to the approval of the Chairpersons so that they can be included in the Scientific Program as either speakers or moderators or both, and should be available for the entire duration of the Scientific Program (Friday, Saturday, and Sunday morning).

Dates: Friday or Saturday
Symposium will be before any scientific sessions

PROVIDED BY THE CONGRESS

Educational Session
• Symposium hall and basic audiovisual equipment

Advertisement Package
• Company profile in the Congress Program Book
• One full page color advertisement in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage
• Brochure in the participants’ bags

Promotion
• Optional simultaneous web cast of Symposium
• Company logo on regular announcements to Congress Database
• Specially-designed mail shots announcing Industrial Symposium to Sponsor’s subsidiaries and affiliates

Breakfast
• A buffet breakfast will be served during the symposium for all the participants.

PROVIDED BY THE COMPANY

Exhibition
• Exhibition space will be charged at a sponsor rate of Euro 450 per each sq.m
SCIENTIFIC SPONSORSHIP OPPORTUNITIES

PLENARY INDUSTRIAL SYMPOSIUM DURING THE CONGRESS
(NON-CME APPROVED)

€50,000

A company may organize an industrial non-CME approved symposium (60-90 minutes) during the day with no parallel scientific sessions simultaneously. The topic will be subject to approval by the Chairpersons of the Conference (Drs. Bressler and Loewenstein) and is expected to follow the controversies theme of the meeting. The Speakers or Moderators will be subject to the approval of the Chairpersons so that they can be included in the Scientific Program as either speakers or moderators or both, and should be available for the entire duration of the Scientific Program (Friday, Saturday, and Sunday morning).

Dates: Friday or Saturday.
Symposium will be allocated within a plenary basis hall with no parallel sessions simultaneously

PROVIDED BY THE CONGRESS

Educational Session
• Plenary symposium hall and basic audiovisual equipment

Advertisement Package
• Company profile in the Congress Program Book
• One full page color advertisement in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage
• Brochure in the participants’ bags

Promotion
• Optional web cast of Symposium
• Company logo on regular announcements to Congress Database
• Specially-designed mail shots announcing Industrial Satellite Symposium to Sponsor’s subsidiaries and affiliates

PROVIDED BY THE COMPANY

Exhibition
• Exhibition space will be charged at a sponsor rate of Euro 450 per each sq.m

*The expenses (travel, accommodation and registration) of the Chairpersons and Speakers of an Industrial Pre or Post-Congress Satellite Symposium are additional and the responsibility of the Sponsor.*
SCIENTIFIC SPONSORSHIP OPPORTUNITIES

YOUNG SCIENTISTS

€30,000

Sponsorship of the travel, registration fees and accommodation (up to three nights) of up to 15 young scientists below the age of 40, who will be selected by the Chairpersons, in consultation with relevant Section Heads of Retina, Anterior Segment, or Glaucoma, based on abstracts submitted and accepted.

PROVIDED BY THE CONGRESS
- Company profile in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage
- The Sponsor will provide selected scientists with complimentary registrations
- Names and contact details of selected scientists
- Representative of the company will be invited to a special ceremony where the winners will be announced and presented with the award.

NEW PLAYERS ON THE BLOCK

€15,000

A company may provide an unrestricted grant for a presentation of 10-15 minutes on a new drug/product to be included in the “New Players” session. Session will be part of the CME sessions, part of the Scientific Program.

PROVIDED BY THE CONGRESS
- Session hall and basic audiovisual equipment
- Company profile in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage
- Brochure in the participants' bags
SCIENTIFIC SPONSORSHIP OPPORTUNITIES

EUROPEAN SPEAKER

€3,000

An unrestricted grant to cover, in part, the expenses of one invited European Speaker. Expenses include travel, accommodation and registration and recognition.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• One full page color advertisement in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage

REGIONAL SPEAKER

(TURKEY, ISRAEL, GULF REGION)

€2,500

An unrestricted grant to cover, in part, the expenses of one invited Regional Speaker. Expenses include travel, accommodation and registration and recognition.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• One full page color advertisement in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage

NORTH AMERICAN, SOUTH AMERICAN, OR ASIAN SPEAKER/S

€6,000

An unrestricted grant to cover, in part, the expenses of one invited Speaker. Expenses include travel, accommodation and registration and recognition.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• One full page color advertisement in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage
SPONSORSHIP OPPORTUNITIES

LUNCH

€25,000
(per lunch)

To subsidize, in part, a buffet lunch to be served to all participants of the Congress.

PROVIDED BY THE CONGRESS
- Four complimentary registrations
- Company profile in the Congress Program Book
- One full page color advertisement in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage
- Brochure in the participants’ bags

WELCOME RECEPTION

SOLE SPONSORSHIP

€10,000

A Welcome Reception for all participants will be held on Thursday evening.

PROVIDED BY THE CONGRESS
- Two complimentary registrations
- 5-minute greeting at the Welcome Reception
- Company logo on the official invitation
- Acknowledgment on special board on-site during the Welcome Reception
- Company profile in the Congress Program Book
- One full page color advertisement in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage
- Brochure in the participants’ bags

FACULTY DINNER

SOLE SPONSORSHIP

€15,000

A dinner will be held for the invited speakers of the Congress.

PROVIDED BY THE CONGRESS
- Two complimentary registrations
- Two seats at the honorary faculty table
- 5-minute greeting at the Faculty Dinner
- Company logo on the official invitation
- Acknowledgment on special board on-site during the Faculty Dinner
- Company profile in the Congress Program Book
- One full page color advertisement in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage
- Brochure in the participants’ bags
SPONSORSHIP OPPORTUNITIES

CONGRESS PROGRAM BOOK

SOLE SPONSORSHIP

€15,000

The Congress Program Book will include the Scientific Program and the Scientific Abstracts, and will be distributed to all participants. This sponsorship opportunity is reserved for Presidential Circle, Platinum and Gold Sponsors, and will be available on a first-come, first-served basis.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• Full page color advertisement on the back cover of the Congress Program Book
• Additional full page color advertisement in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage

INTERNET CENTER

SOLE SPONSORSHIP

€10,000

The Internet Center will be outfitted with internet workstations for participants of the Congress to stay updated between sessions.

THE SPONSOR MAY

• Display logo as a screensaver
• Display logo on screen background

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage

PARTICIPANTS’ BAGS

SOLE SPONSORSHIP

provided-in-kind + €10,000

The opportunity to provide branded bags for all participants of the Congress. This sponsorship opportunity is reserved for Presidential Circle, Platinum and Gold Sponsors, and will be available on a first-come, first-served basis.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage
• Brochure in the participants’ bags
SPONSORSHIP OPPORTUNITIES

ABSTRACTS ON THE WEBSITE

SOLE SPONSORSHIP

€8,000

The Scientific Abstracts of the Congress will be placed on the Congress Website and will be available for a limited period.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage

POCKET PROGRAM

SOLE SPONSORSHIP

€8,000

A Pocket Program will be distributed to all participants in their Congress Kits. This sponsorship opportunity is reserved for Presidential Circle, Platinum and Gold Sponsors, and will be available on a first-come, first-served basis.

PROVIDED BY THE CONGRESS

• Exclusive advertisement on the back cover of the Pocket Program
• Company profile in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage
• Brochure in the participants’ bags

TRANSLATION

€5,000

(per hall, per day)

Simultaneous translation from English into any required language.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage

WRITING PADS AND PENS

SOLE SPONSORSHIP

provided-in-kind + €5,000

The opportunity to provide branded writing pads and pens that will be included in the participants’ bags. Except where precluded by a participant’s regional laws.

PROVIDED BY THE CONGRESS

• Company profile in the Congress Program Book
• Acknowledgment: Congress Website, Congress Program Book, on-site Signage
SPONSORSHIP OPPORTUNITIES

CONGRESS LANYARDS

The Sponsor will provide printed lanyards for the name badges

\( \text{€5,000} \)

The Congress will provide printed lanyards for the name badges

\( \text{€8,000} \)

This sponsorship opportunity is reserved for Presidential Circle, Platinum and Gold Sponsors, and will be available on a first-come, first-served basis and will be included at registration, except where precluded by a participant’s regional laws.

PROVIDED BY THE CONGRESS

- Company profile in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage

BROCHURE INSERT

\( \text{€3,000} \)

Company brochure to be inserted into the participants’ bags, which will be distributed at the Congress.

PROVIDED BY THE CONGRESS

- Company profile in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage

COFFEE BREAK

\( \text{€3,000} \)

(per coffee break)

There will be daily coffee breaks between sessions throughout the Congress.

PROVIDED BY THE CONGRESS

- Company profile in the Congress Program Book
- Acknowledgment: Congress Website, Congress Program Book, on-site Signage

TAILOR-MADE SPONSORSHIP PACKAGES

Sponsorship packages may be tailored to suit the Sponsor's marketing strategy in order to maximize visibility, and to best promote products and services. Please contact the Congress Organizer for further details on creating the appropriate package.

Terms and Conditions:

- All sponsorship and exhibition prices quoted are in € and are subject to VAT
- Time slot allocation will be based on level of sponsorship and approval from the Scientific Committee
- It is the responsibility of the Sponsors and Exhibitors to comply with the regulations of the local authorities, EFPIA (European Federation of Pharmaceutical Industries & Associations) www.efpia.org and IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) www.ifpma.org Code of Practice on the Promotion of Medicines
- The Congress Organizers reserves the right to accept or decline offers of sponsorship and application for exhibition space
- The Congress Organizer reserves the right to amend the published floor plan should it be felt that such an amendment would benefit the exhibition and the Congress as a whole
- Please note that the Congress Organizer must approve all exhibition stand designs
EXHIBITION

An exhibition will be held in conjunction with the Congress. The exhibition floor plan is designed to maximize exposure to the participants. All lunches and coffee breaks will be held in the exhibition area daily.

Exhibition space will be available on a first-come, first-served basis, with priority given to Presidential Circle, Platinum and Gold Sponsors.

Exhibition space will be available as follows:
The cost for exhibition space rental is €650 per sq.m.
Companies who will contribute minimum of €25,000 will be entitled to a special sponsors’ rate of €450 per sq.m.
The minimum booth size is 2 x 3 sq.m.

Please visit www.comtecmad.com/cophy to view the exhibition floorplan.

Exhibition space rental is priced according to size (per sq.m) and includes:
• Net stand area
• Company profile in Congress Program Book
• Two exhibitor registrations
• Exhibitors’ Manual
• General cleaning of public areas
• Venue security

Stand equipment and additional services may be ordered by means of the forms in the Exhibitors’ Manual: Furniture, partition walls, carpets, telephone and data lines, electricity, stand cleaning, exhibitors’ insurance, logistics, among other services.
GENERAL INFORMATION

VENUE
Swissôtel The Bosphorus, Istanbul
Bayildim Cad. No:2
Macka, Besiktas, Istanbul 34357, Turkey
Tel: +90 212 326 1100
Fax: +90 212 326 1122
www.swissotel.com/istanbul

LANGUAGE
The official language of the Congress is English.

CONGRESS ORGANIZER AND SPONSORSHIP / EXHIBITION CONTACT:
ComtecMed
53, Rothschild Boulevard, PO Box 68
Tel Aviv, 61000, Israel
Tel: +972 3 5666166
Fax: +972 3 5666177
E-mail: cophy@comtecmed.com
Website: www.comtecmed.com/cophy

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>Early Registration until January 7, 2012</th>
<th>Late Registration from January 8 until March 16, 2012</th>
<th>From March 17, 2012 and On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants - Physicians and Scientists</td>
<td>€450</td>
<td>€490</td>
<td>€540</td>
</tr>
<tr>
<td>Trainees*, Nurses, Students</td>
<td>€320</td>
<td>€370</td>
<td>€420</td>
</tr>
</tbody>
</table>

* Refers to non-tenured junior scientists. Registration forms must be accompanied by a letter from the head of the department, confirming their status. The letter should be printed on a department letterhead and addressed to the Registration Department of the Congress.

Registration fees include: participation in scientific sessions, Congress bag, program and abstract book, all printed material of the congress, invitation to the Welcome Reception and coffee breaks.

LIABILITY AND INSURANCE
The Congress Organizer cannot accept liability for personal accidents, or for loss of or damage to private property of participants, either during or directly arising from the Congress. Participants should make their own arrangements with respect to health and travel insurance.
The 3rd World Congress on CONTROVERSIES IN OPHTHALMOLOGY
Anterior Segment, Retina, Glaucoma

ISTANBUL, TURKEY • MARCH 22-25, 2012

SECTION HEADS

■ ANTERIOR SEGMENT
  J. Alio, Spain
  E. Assia, Israel
  W.J. Stark, USA

■ RETINA
  (INCL. UVEITIS, TUMORS & TRAUMA)
  A. Augustin, Germany
  F. Bandello, Italy
  S. Bressler, USA
  J. Moisseiev, Israel

■ GLAUCOMA
  A. Heijl, Sweden
  K. Martin, UK

■ OTHER
  (NEURO-OPHTHALMOLOGY & PEDIATRICS)
  N. Miller, USA
  K.K. Nischal, UK

SPONSORS

PRESIDENTIAL CIRCLE

BAUSCH + LOMB

PLATINUM

ALLERGAN
ophthalmology

GOLD

NOVARTIS

SPONSOR

LUMENIS. iVision
Enhancing Life. Advancing Sight.